InMed Pharmaceuticals to Merge with Mentari Therapeutics in All-Stock Deal, Secures $290M Financing
INM has more than doubled off its 52-week low of $0.575 on elevated volume (57× avg).
Summary
InMed Pharmaceuticals is merging with Mentari Therapeutics in an all-stock transaction, backed by a $290 million private placement, to pivot into migraine prevention therapies and secure long-term funding.
Key Events · M&A and Partnerships · INM
-
Transformative Merger Announced
InMed Pharmaceuticals Inc. will merge with privately-held Mentari Therapeutics, Inc. in an all-stock transaction, with the combined entity operating as Mentari Therapeutics.
-
Significant Capital Raise
A concurrent oversubscribed private placement of $290 million is expected to fund the combined company's operations through 2028, addressing InMed's prior going concern issues.
-
New Ownership Structure
Pre-merger InMed shareholders are expected to own approximately 1.51% of the combined company, which will have a pro forma equity value of approximately $421.4 million.
-
Focus on Migraine Prevention Pipeline
The combined company will advance Mentari's pipeline of migraine prevention therapies, including MT-001 (anti-PACAP) and MT-002 (anti-CGRP x PACAP bispecific), with key clinical data expected by 2028 and 2027, respectively.
Analysis · INM · Life Sciences
InMed Pharmaceuticals is undergoing a transformative merger with privately-held Mentari Therapeutics, effectively becoming Mentari Therapeutics. This all-stock transaction includes a substantial $290 million concurrent private placement, which is expected to fund the combined company's operations through 2028. The deal addresses InMed's previously reported going concern doubt and short cash runway, providing a new strategic direction focused on migraine prevention therapies. While existing InMed shareholders will own approximately 1.51% of the combined entity, they will receive Contingent Value Rights (CVRs) representing 90% of net proceeds from the sale of InMed's pre-merger legacy assets. This event fundamentally alters the company's business, capital structure, and future prospects.
At the time of this filing, INM was trading at $1.39 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2.3M. The 52-week trading range was $0.58 to $7.98. This filing was assessed with positive market sentiment and an importance score of 10 out of 10.